Raymond James & Associates’s Repligen RGEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $12.2M | Buy |
82,277
+27,158
| +49% | +$3.89M | 0.01% | 1106 |
|
|
2024
Q2 | $6.95M | Buy |
55,119
+1,951
| +4% | +$306K | ﹤0.01% | 1368 |
|
|
2024
Q1 | $9.78M | Buy |
53,168
+6,444
| +14% | +$1.23M | 0.01% | 1165 |
|
|
2023
Q4 | $8.4M | Sell |
46,724
-20,495
| -30% | -$3.19M | 0.01% | 1211 |
|
|
2023
Q3 | $10.7M | Buy |
67,219
+2,283
| +4% | +$373K | 0.01% | 1001 |
|
|
2023
Q2 | $9.19M | Sell |
64,936
-10,731
| -14% | -$1.72M | 0.01% | 1105 |
|
|
2023
Q1 | $12.7M | Sell |
75,667
-11,244
| -13% | -$2.01M | 0.01% | 893 |
|
|
2022
Q4 | $14.7M | Sell |
86,911
-529
| -0.6% | -$96K | 0.01% | 803 |
|
|
2022
Q3 | $16.4M | Sell |
87,440
-6,973
| -7% | -$1.47M | 0.02% | 706 |
|
|
2022
Q2 | $15.3M | Buy |
94,413
+26,791
| +40% | +$4.24M | 0.02% | 743 |
|
|
2022
Q1 | $12.7M | Buy |
67,622
+28,324
| +72% | +$5.38M | 0.01% | 944 |
|
|
2021
Q4 | $10.4M | Sell |
39,298
-1,077
| -3% | -$290K | 0.01% | 1082 |
|
|
2021
Q3 | $11.7M | Buy |
40,375
+2,607
| +7% | +$669K | 0.01% | 971 |
|
|
2021
Q2 | $7.54M | Sell |
37,768
-49
| -0.1% | -$9.51K | 0.01% | 1228 |
|
|
2021
Q1 | $7.35M | Sell |
37,817
-4,367
| -10% | -$895K | 0.01% | 1207 |
|
|
2020
Q4 | $8.08M | Sell |
42,184
-941
| -2% | -$171K | 0.01% | 1070 |
|
|
2020
Q3 | $6.36M | Buy |
43,125
+16,712
| +63% | +$2.39M | 0.01% | 1095 |
|
|
2020
Q2 | $3.27M | Buy |
26,413
+14,976
| +131% | +$1.76M | ﹤0.01% | 1439 |
|
|
2020
Q1 | $1.1M | Buy |
11,437
+1,678
| +17% | +$162K | ﹤0.01% | 1917 |
|
|
2019
Q4 | $903K | Sell |
9,759
-418
| -4% | -$35.1K | ﹤0.01% | 2328 |
|
|
2019
Q3 | $780K | Sell |
10,177
-519
| -5% | -$45.4K | ﹤0.01% | 2343 |
|
|
2019
Q2 | $919K | Buy |
10,696
+5,504
| +106% | +$375K | ﹤0.01% | 2269 |
|
|
2019
Q1 | $307K | Buy |
+5,192
| New | +$299K | ﹤0.01% | 2968 |
|
|
2016
Q3 | – | Sell |
-11,921
| Closed | -$326K | – | 3280 |
|
|
2016
Q2 | $326K | Buy |
11,921
+879
| +8% | +$22.5K | ﹤0.01% | 2364 |
|
|
2016
Q1 | $296K | Buy |
+11,042
| New | +$270K | ﹤0.01% | 2344 |
|
|
2015
Q4 | – | Sell |
-12,095
| Closed | -$337K | – | 2386 |
|
|
2015
Q3 | $337K | Sell |
12,095
-708
| -6% | -$25.6K | ﹤0.01% | 2095 |
|
|
2015
Q2 | $528K | Buy |
12,803
+1,088
| +9% | +$39.9K | ﹤0.01% | 2071 |
|
|
2015
Q1 | $356K | Buy |
+11,715
| New | +$304K | ﹤0.01% | 2159 |
|
|
2014
Q4 | – | Sell |
-12,986
| Closed | -$259K | – | 2291 |
|
|
2014
Q3 | $259K | Buy |
12,986
+2,000
| +18% | +$42.1K | ﹤0.01% | 2087 |
|
|
2014
Q2 | $250K | Buy |
+10,986
| New | +$196K | ﹤0.01% | 2107 |
|
Other funds holding RGEN
CIP
BCM
Raymond James & Associates's RGEN Position: Q3 2024 in Review
Raymond James & Associates increased its Repligen (RGEN) stake by 49% in Q3 2024, buying an estimated $3.89M and bringing the position to 82,277 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #1106.
Raymond James & Associates first reported a position in RGEN in Q2 2014 and has held it in 30 quarters since. The position peaked at $16.4M in Q3 2022. 444 funds tracked by Wall St. Rank hold RGEN as of Q3 2024.
- Raymond James & Associates held 82,277 shares of Repligen worth $12.2M as of Q3 2024.
- Raymond James & Associates bought 27,158 Repligen shares in Q3 2024, an estimated $3.89M.
- Repligen made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1106 holding.
- Raymond James & Associates first reported a position in Repligen in Q2 2014 and has held it in 30 quarters since.
- Raymond James & Associates's Repligen position peaked at $16.4M in Q3 2022.
- 444 funds tracked by Wall St. Rank held Repligen as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.